Vaxart, Inc. (NASDAQ:VXRT) Short Interest Update

Vaxart, Inc. (NASDAQ:VXRT) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 13,280,000 shares, a growth of 17.0% from the February 13th total of 11,350,000 shares. Based on an average trading volume of 1,960,000 shares, the short-interest ratio is presently 6.8 days. Currently, 6.0% of the shares of the company are sold short.

Hedge Funds Weigh In On Vaxart

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Vaxart by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company’s stock valued at $1,723,000 after acquiring an additional 57,911 shares during the period. Silverarc Capital Management LLC increased its stake in Vaxart by 7.8% during the fourth quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company’s stock valued at $714,000 after acquiring an additional 77,782 shares during the period. Squarepoint Ops LLC increased its stake in Vaxart by 95.0% during the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company’s stock valued at $342,000 after acquiring an additional 251,789 shares during the period. Raymond James Financial Inc. bought a new position in Vaxart during the fourth quarter valued at about $129,000. Finally, Bank of America Corp DE grew its stake in shares of Vaxart by 10.8% in the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 17,942 shares during the period. 18.05% of the stock is currently owned by institutional investors.

Vaxart Stock Down 0.9 %

Shares of VXRT opened at $0.57 on Wednesday. Vaxart has a 12-month low of $0.45 and a 12-month high of $1.41. The firm has a market capitalization of $129.66 million, a price-to-earnings ratio of -1.39 and a beta of 1.69. The stock’s 50-day moving average price is $0.66 and its 200 day moving average price is $0.71.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.